An Evaluation of Patient Reported Outcomes and Clinical Outcomes

Active, not recruitingOBSERVATIONAL
Enrollment

379

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Post-Operative Complications in Cardiac Surgery
Interventions
DRUG

RBT-1

Intravenous administration

DRUG

Placebo

Intravenous administration

Trial Locations (39)

11355

New York Presbyterian-Queens, Flushing

20010

Research Site, Washington D.C.

22903

Research Site, Charlottesville

27157

Research Site, Winston-Salem

27610

Research Site, Raleigh

30342

Research Site, Atlanta

30606

Research Site, Athens

32608

Research Site, Gainesville

33462

Research Site, Atlantis

35801

Research Site, Huntsville

37203

Research Site, Nashville

43606

Research Site, Toledo

44106

Research Site, Cleveland

46202

Research Site, Indianapolis

46237

Research Site, Indianapolis

46804

Research Site, Fort Wayne

48073

Research Site, Royal Oak

48109

Research Site, Ann Arbor

48670

Research Site, Midland

48879

Research Site, Lansing

55905

Research Site, Rochester

63310

Research Site, St Louis

66160

Research Site, Kansas City

75390

Research Site, Dallas

77030

Research Site, Houston

78229

Research Site, San Antonio

94107

Research Site, San Francisco

94305

Research Site, Stanford

02115

Research Site, Boston

V1Y 0C5

Research Site, Kelowna

E2L 4L2

Research Site, Saint John

A1B 3V6

Research Site, St. John's

L8L 2X2

Research Site, Hamilton

K7L 2V7

Research Site, Kingston

H1T 1C8

Research Site, Montreal

H2X 0C1

Research Site, Montreal

H4A 3J1

Research Site, Montreal

H4J 1C5

Research Site, Montreal

G1V 4G5

Research Site, Québec

All Listed Sponsors
lead

Renibus Therapeutics, Inc.

INDUSTRY

NCT06092970 - An Evaluation of Patient Reported Outcomes and Clinical Outcomes | Biotech Hunter | Biotech Hunter